| Today’s Big NewsOct 6, 2023 |
|
The New QPS Therapeutic RNAi White Paper discusses the past, present and future utility of RNAi therapeutics in disease treatments. QPS is the ideal partner to help develop custom-built solutions that forge efficient drug development pathways. Learn more.
 |
|
| By Angus Liu Amgen has completed its $27.8 billion acquisition of Horizon Therapeutics after fending off a legal challenge by the U.S. antitrust watchdog. |
|
|
|
By Andrea Park Since Philips began its recall of millions of respiratory devices in June 2021, the FDA hasn’t been shy about criticizing how the company has handled the recall. |
By James Waldron Outside of a global pandemic, it’s rare for a medicine to truly become a household name. But Novo Nordisk’s Wegovy is rapidly reaching that status, with the obesity drug accruing more front pages and celebrity endorsers every day. |
By Kevin Dunleavy People who use Novo Nordisk’s popular weight-loss drugs are taking on a small risk of developing severe stomach problems, according to research conducted by the University of British Columbia. The investigation indicates a link between Novo’s GLP-1 products and gastroparesis, pancreatitis and bowel obstruction. Still, the investigators emphasized that the risk was very small. |
|
Thursday, October 12, 2023 | 11am ET / 8am PT A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks? In this webinar, leaders in industry and academia discuss their experiences using innovative tools to study and develop therapeutics against influenza, SARS-CoV-2, dengue viruses, and more. Register now. 
|
|
By Nick Paul Taylor Bristol Myers Squibb is putting Paradigm’s plans to rebuild the clinical trial system to the test, teaming up with the startup to design studies that can activate community health provider organizations as sites. |
By Conor Hale The spinout from Dana-Farber Cancer Institute aims to deliver a series of blood tests aimed not only at directing patients to precision treatments, but also at assisting drug developers in creating new ones. |
By Zoey Becker The National Comprehensive Cancer Network found that 72% of centers are still experiencing a carboplatin shortage, while 59% remain low on cisplatin. The survey follows a June report which found that nearly all centers had short supply of the chemotherapies. |
By Angus Liu,Eric Sagonowsky Mirati Therapeutics saw its stock price spike Thursday at the possibility of a buyout from Sanofi. The French pharma has been evaluating a potential acquisition of the KRAS drug developer, Bloomberg reports, citing unnamed sources. |
By Max Bayer,Gabrielle Masson With Eli Lilly on the precipice of one of its most consequential FDA approvals ever, the company is making major executive moves. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
|
Thursday, October 12, 2023 | 2pm ET / 11am PT In this webinar, we take a deep dive into different strategies for unifying enterprise-wide lab data. You'll learn how to drive better access, collaboration, and AI-driven insight. Don't miss out, register today. 
|
|
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| |
|
